Literature DB >> 303258

Mechanism for induction of anti-DNA antibodies by bacterial lipopolysaccharides in mice; II. Correlation between anti-DNA induction and polyclonal antibody formation by various polyclonal B lymphocyte activators.

S Izui, T Kobayakawa, M J Zryd, J Louis, P H Lambert.   

Abstract

The capacity of various polyclonal B lymphocyte activators (PBA) to induce, in mice, the formation of anti-DNA antibodies was compared with their ability to mediate the release of DNA in circulating blood and to stimulate polyclonal antibody synthesis in vivo. Anti-DNA antibodies or polyclonal antibody synthesis were induced in mice after the injection of at least 10 microgram lipopolysaccaride (LPS) from Salmonella typhimurium, 1 mg dextran sulfate (DS), or 2 mg purified protein derivative of tubercle bacteria RT32 (PPD). Smaller quantities of LPS (0.1 microgram) or DS (500 microgram) were sufficient to cause the release of DNA in circulating blood, whereas PPD was not able to provoke such a release at any concentration used. The association of anti-DNA antibodies with polyclonal antibody synthesis in mice injected with various PBA contrasts with the lack of correlation between the formation of anti-DNA antibodies and the release of measurable amounts of DNA in circulating blood. These results strongly suggest that the induction of anti-DNA antibodies by PBA is a consequence of the polyclonal B lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 303258

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

Review 2.  Polyclonal activators in pulmonary immune disease.

Authors:  W F Willoughby; J B Willoughby; G F Gerberick
Journal:  Clin Rev Allergy       Date:  1985-05

3.  Guinea pigs with inherited deficiencies of complement components C2 or C4 have characteristics of immune complex disease.

Authors:  E C Böttger; T Hoffmann; U Hadding; D Bitter-Suermann
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

4.  Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis.

Authors:  B Galvão-Castro; J A Sá Ferreira; K F Marzochi; M C Marzochi; S G Coutinho; P H Lambert
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

5.  Single stranded DNA binding antibodies in patients with obstructive jaundice.

Authors:  G Ohshio; F Furukawa; T Manabe; T Tobe; Y Hamashima
Journal:  Jpn J Surg       Date:  1985-03

6.  Glomerular lesions induced in the rabbit by physicochemically altered homologous IgG.

Authors:  F Cavalot; M Miyata; A Vladutiu; V Terranova; S Dubiski; R Burlingame; E Tan; J Brentjens; F Milgrom; G Andres
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

7.  Injection of mouse thyroglobulin and/or adult thymectomy do not break tolerance to thyroglobulin during the lupus like graft versus host disease in mice.

Authors:  F M van Rappard-van der Veen; Y M Kong; N R Rose; M Kimura; E Gleichmann
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  Thymocytotoxic autoantibodies found in mice infected with Schistosoma japonicum.

Authors:  M Kawabata; Y Hosaka; M Kumada; N Matsui; T Kobayakawa
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

9.  Rheumatoid factors in mice: non-specific activators of heterophile rheumatoid factor production.

Authors:  A M Popham; D W Dresser
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

10.  Anti-ssDNA and antinuclear antibodies in human malaria.

Authors:  D Adu; D G Williams; I A Quakyi; A Voller; Y Anim-Addo; A A Bruce-Tagoe; G D Johnson; E J Holborow
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.